Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2021

01-01-2021 | Breast Cancer | Brief Research Article

Hypofractionated whole breast irradiation after IORT treatment: evaluation of acute toxicity and cosmesis

Authors: J. Burgos-Burgos, V. Vega, D. Macias-Verde, V. Gómez, M. Travieso-Aja, J. Travieso, E. Vicente, C. Santana, J. Ospina, P. C. Lara

Published in: Clinical and Translational Oncology | Issue 1/2021

Login to get access

Abstract

Introduction

Hypofractionated whole breast irradiation (HWBI) is the current standard of treatment after breast conservative surgery (BCS). Intraoperative radiotherapy (IORT) must be associated to WBI in patients showing high-risk factors of local recurrence in the definitive pathology report. The aim of this trial was to evaluate, for the first time, the acute toxicity and cosmesis of HWBI after photon-IORT.

Materials and methods

Twenty-six luminal breast cancer patients treated by BCS and IORT(20 Gy) were included between February and December 2019, in this prospective trial, of adjuvant HWBI (40.5 Gy/2.67 Gy/15 fractions). Acute toxicity (CTCAEv5.0) and cosmesis (Harvard scale), were assessed 3 months after treatment.

Results

All patients completed their treatment without interruptions. All cases were evaluable 3 months after treatment showing no toxicity ≥ G3 and excellent/good cosmesis assessment in 88% of the patients.

Conclusion

HWBI seems to have similar acute toxicity and cosmesis results than conventionally fractionated WBI in combination to photon-IORT after BCS.
Literature
1.
Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011;378:1707–16.CrossRef
2.
Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62(740):679–94.CrossRef
3.
Haviland JS, Bentzen SM, Bliss JM, Yarnold JR, START Trial Management Group. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: an analysis of the UK START (standardization of breast radiotherapy) trials of radiotherapy fractionation. Radiother Oncol. 2016;121:420–3.CrossRef
4.
Fowble B, Solin LJ, Schultz DJ, et al. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. 1990;19:833–42.CrossRef
5.
Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376:91–102.CrossRef
6.
Vaidya JS, Baum M, Tobias JS, et al. Long- term results of TARGeted intraoperative radioTherapy (Targit) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2011;81(4):1091–7.CrossRef
7.
Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRef
8.
Blank E, Kraus-Tiefenbacher U, Welzel G, et al. Single-center long-term follow-up after intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage x-rays. Ann Surg Oncol. 2010;17(3):352–8.CrossRef
9.
Radiation Therapy Oncology Group (RTOG) https://​www.​rtog.​org/​CoreLab/​ContouringAtlase​s.​aspx
10.
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 2017. https://​ctep.​cancer.​gov/​docs/​CTCAE_​v5_​Quick_​Reference_​5x7
11.
Harris JR, Levene MB, Svensson G, et al. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1979;5(2):257–61.CrossRef
12.
13.
Smith BD, Bellon J, Blitzblau R, et al. Radiation therapy for the whole breast: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Prac Radiat Oncol. 2018;3:145–52.CrossRef
14.
15.
Fastner G, Reitsamer R, Murawa D, et al. Hypofractionated WBI plus IOERT-boost in early stage breast cancer (HIOB): updated results of a prospective trial [Abstract]. Radiother Oncol. 2015;115(1):S233–S234234.CrossRef
16.
Joseph DJ, Bydder S, Jackson LR, et al. Prospective trial of intraoperative radiation treatment for breast cancer. Anz J Surg. 2004;74:1043–8.CrossRef
17.
Kraus-Tiefenbacher U, Bauer L, Kehrer T, et al. Intraoperative radiotherapy (IORT) as a boost in patients with early stage breast cancer—acute toxicity. Onkologie. 2006;29(3):77–82.PubMed
18.
Lee JJ, Choi J, Gwen S, et al. In vivo dosimetry and acute toxicity in breast cancer patient undergoing intraoperative radiotherapy as boost. Radiot Oncol J. 2017;35(2):121–8.CrossRef
19.
Anh SG, Bae SJ, Lee HW, et al. A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients. Breast Cancer Res Treat. 2018;174(1):157–63.
Metadata
Title
Hypofractionated whole breast irradiation after IORT treatment: evaluation of acute toxicity and cosmesis
Authors
J. Burgos-Burgos
V. Vega
D. Macias-Verde
V. Gómez
M. Travieso-Aja
J. Travieso
E. Vicente
C. Santana
J. Ospina
P. C. Lara
Publication date
01-01-2021
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2021
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02400-z

Other articles of this Issue 1/2021

Clinical and Translational Oncology 1/2021 Go to the issue

Research Article

Effect of shRNA-mediated regulation of S100A4 gene expression on proliferation and apoptosis of KLE endometrial cancer cells

Research Article

Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study

Editorial

Low-dose radiation therapy: could it be a game-changer for COVID-19?

Research Article

Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group

Research Article

Positioning error analysis of the fraxion localization system in the intracranial stereotactic radiotherapy of tumors

Research Article

Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits